isr20240116_8ka.htm
Form 8-K/A date of report 01-08-24
true
0000728387
0000728387
2024-01-08
2024-01-08
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K/A
Amendment No. 1
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): January 8, 2024
Perspective Therapeutics, Inc.
(Exact Name of Registrant as Specified in its Charter)
Delaware
|
|
001-33407
|
|
41-1458152
|
(State or Other Jurisdiction
of Incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
2401 Elliott Avenue, Suite 320, Seattle, Washington
|
|
98121
|
(Address of Principal Executive Offices)
|
|
(Zip Code)
|
Registrant’s telephone number, including area code: (206) 676-0900
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
|
|
Trading
Symbol(s)
|
|
Name of each exchange
on which registered
|
Common Stock, par value $0.001 per share
|
|
CATX
|
|
NYSE American
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Explanatory Note
As previously reported by Perspective Therapeutics, Inc. (the “Company”) on a Current Report on Form 8-K filed with the Securities and Exchange Commission on January 11, 2024 (the “Initial Form 8-K”), the Company entered into that certain (i) Investment Agreement (the “Investment Agreement”), dated January 8, 2024, with Lantheus Alpha Therapy, LLC, a Delaware limited liability company (“Lantheus”), (ii) Asset Purchase Agreement (the “Asset Purchase Agreement”), dated January 8, 2024, with Progenics Pharmaceuticals, Inc., a Delaware corporation, and (iii) Option Agreement (the “Option Agreement” and together with the Investment Agreement and the Asset Purchase Agreement, the “Agreements”), dated January 8, 2024, with Lantheus.
This Current Report on Form 8-K/A (“Amendment No. 1”) is being filed as an amendment to the Initial Form 8-K to file, as exhibits under Item 9.01(d), copies of the Investment Agreement, Asset Purchase Agreement and Option Agreement, which are attached hereto as Exhibits 10.1, 10.2 and 10.3, respectively. This Amendment No. 1 supplements the Initial Form 8-K and should be read in conjunction with the Initial Form 8-K.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
Exhibit
No.
|
|
Description
|
10.1*+
|
|
|
10.2*
|
|
|
10.3*+
|
|
|
104
|
|
The cover page from this Current Report on Form 8-K, formatted in Inline XBRL.
|
*
|
Certain portions of this exhibit (indicated by asterisks) have been omitted pursuant to Item 601(b)(10)(iv) of Regulation S-K.
|
+
|
Certain schedules and exhibits have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The Company will furnish supplementally a copy of any omitted schedule or exhibit to the Securities and Exchange Commission upon request. The Company may request confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended, for any schedules or exhibits so furnished.
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
PERSPECTIVE THERAPEUTICS, INC.
|
|
|
|
|
|
|
|
|
|
Date: January 17, 2024
|
By:
|
/s/ Johan (Thijs) Spoor
|
|
|
|
Johan (Thijs) Spoor
|
|
|
|
Chief Executive Officer
|
|